Investment case
Gossamer Bio, Inc.
GOSS · 2 developments mapped · last assessed 2026-09-09
Market Ontology has mapped 2 macro, policy, and market developments to Gossamer Bio, Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for GOSS yet, so no modelled value is shown. The GOSS valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run GOSS on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Gossamer Bio Announces 1-for-80 Reverse Stock Split
A reverse stock split, while technically neutral to market capitalization, is often perceived negatively by investors as it frequently indicates a company's struggle to maintain its stock price above exchange minimums. This can lead to reduced investor confidence, increased short-selling interest, a
· Moves perceived risk premium (increasing wacc), investor sentiment and liquidity, future equity financing terms
- Open question
Gossamer Bio, Inc. Follow-On — $250M
Direct equity dilution, increased cash runway, reduced near-term bankruptcy risk, potential for increased R&D spend, and market perception of financing terms.
· Moves equity value per share, cost of equity, probability of success for seralutinib
What changed, by assumption
- 2026-09-09Gossamer Bio Announces 1-for-80 Reverse Stock Split
- 2026-08-21Gossamer Bio, Inc. Follow-On — $250M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-21 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-21 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-07-01 | Interest expense | Bullish | Coupon adds to interest expense until conversion. | 0.70 |
| 2026-07-01 | Dilution | Bullish | Convertible issuance creates contingent dilution at conversion price. | 0.70 |
| 2026-06-17 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-06-17 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-06-17 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
| 2026-06-17 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-06-17 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-09 | Gossamer Bio Announces 1-for-80 Reverse Stock Split | Bearish | 1-3m | 0.80 |
| 2026-08-21 | Gossamer Bio, Inc. Follow-On — $250M | mixed | 1-3m | 0.80 |